SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Rodberg James (Last) (First) (Middle) C/O SIGHT SCIENCES, INC. 4040 CAMPBELL AVE., SUITE 100 (Street) MENLO PARK CA 94025 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/08/2023	3. Issuer Name and Ticker or Trading Symbol Sight Sciences, Inc. [ SGHT ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) See Remarks	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	699	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	05/16/2022(1)	05/24/2031	Common Stock	27,500	10.96	D
Stock Options (Right to Buy)	02/01/2022(2)	02/08/2032	Common Stock	13,100	17.52	D
Restricted Stock Units	(3)	(3)	Common Stock	22,300	(4)	D
Restricted Stock Units	(5)	(5)	Common Stock	3,300(5)	(4)	D

Explanation of Responses:

1. These options were granted on May 25, 2021 and became exercisable as to 25% of the underlying securities May 16, 2022, with the remainder vesting in 36 substantially equal installments on a monthly basis thereafter, subject to the Reporting Person's continued service to the Company through each such date.

2. These options were granted on February 9, 2022 and vest in 48 substantially equal installments on a monthly basis commencing February 1, 2022, subject to the Reporting Person's continued service to the Company through each such date.

3. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs shall vest in four equal installments on an annual basis from December 1, 2023 through December 1, 2026 subject to the Reporting Person's continued service to the Company through each vesting date. The RSUs have no expiration date.

4. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

5. Reflects a grant of 4,400 RSUs made to the Reporting Person under the 2021 Plan, 1,100 of which vested on January 1, 2023. The remaining 3,300 RSUs shall vest in three equal installments on an annual basis from January 1, 2024 through January 1, 2026 subject to the Reporting Person's continued service to the Company through each vesting date. The RSUs have no expiration date.

Remarks:

Interim Chief Financial Officer Exhibit list: Exhibit 24 - Power of Attorney

	/s/ Jeremy Hayden, Attorney-in-Fact for James Rodberg	01/18/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

                                                                      EXHIBIT 24

                               POWER OF ATTORNEY

      With respect to holdings of and transactions in securities issued by Sight
Sciences, Inc. (the "Company"), the undersigned hereby constitutes and appoints
the individuals named on Schedule A attached hereto and as may be amended from
time to time, or any of them signing singly, with full power of substitution and
resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

1.    prepare, execute in the undersigned's name and on the undersigned's
      behalf, and submit to the United States Securities and Exchange Commission
      (the "SEC") a Form ID, including amendments thereto, and any other
      documents necessary or appropriate to obtain and/or regenerate codes and
      passwords enabling the undersigned to make electronic filings with the SEC
      of reports required by Section 16(a) of the Securities Exchange Act of
      1934, as amended, or any rule or regulation of the SEC;

2.    execute for and on behalf of the undersigned, Forms 3, 4, and 5 in
      accordance with Section 16 of the Securities Exchange Act of 1934, as
      amended, and the rules thereunder;

3.    do and perform any and all acts for and on behalf of the undersigned which
      may be necessary or desirable to complete and execute any such Form 3, 4,
      or 5, complete and execute any amendment or amendments thereto, and timely
      file such form with the SEC and any stock exchange or similar authority;
      and

4.    take any other action of any type whatsoever in connection with the
      foregoing which, in the opinion of such attorney-in-fact, may be of
      benefit to, in the best interest of, or legally required by, the
      undersigned, it being understood that the documents executed by such
      attorney-in-fact on behalf of the undersigned pursuant to this Power of
      Attorney shall be in such form and shall contain such terms and conditions
      as such attorney-in-fact may approve in such attorney-in-fact's
      discretion.

      The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.

      The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 3rd day of January, 2023.


                                           Signature:   /s/ James Rodberg
                                           Print Name: James Rodberg




                                   Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and
Resubstitution:

Rick Dykstra
Jeremy Hayden
Ryan C. Wilkins